Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 151,011,920
  • Shares Outstanding, K 2,262,690
  • Annual Sales, $ 26,145 M
  • Annual Income, $ 3,439 M
  • 60-Month Beta 0.67
  • Price/Sales 3.74
  • Price/Cash Flow 15.16
  • Price/Book 3.00
Trade BMY with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 1.37
  • Number of Estimates 6
  • High Estimate 1.39
  • Low Estimate 1.34
  • Prior Year 1.22
  • Growth Rate Est. (year over year) +12.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.47 +9.57%
on 01/05/21
67.16 -1.35%
on 01/19/21
+3.13 (+4.96%)
since 12/18/20
3-Month
56.75 +16.73%
on 10/29/20
67.16 -1.35%
on 01/19/21
+5.61 (+9.25%)
since 10/20/20
52-Week
45.76 +44.78%
on 03/23/20
68.34 -3.06%
on 01/22/20
-0.47 (-0.70%)
since 01/17/20

Most Recent Stories

More News
Sickle Cell Disease Treatment Market to Exhibit a CAGR of 18.5% and Reach USD 7.71 Billion by 2027; FDA Approval for Emmaus's Endari to Aid Development, states Fortune Business Insights(TM)

The global sickle cell disease treatment market size is expected to reach USD 7.71 billion in 2027, exhibiting a CAGR of 18.5% during the forecast period. The unmet needs of patients and lack of novel...

BMY : 66.25 (-0.73%)
GBT : 48.26 (-5.09%)
Skin Cancer Diagnostics and Therapeutics Market Research 2020, Consumption, Companies , Industry Report Analysis and Future Demand By 2025

(MENAFN - Comserve) Shibuya-ku, Tokyo, Japan, Japan, Jan 20, 2021, 03:01 /Comserve / -- The report offers overview of leading companies encompassing their successful marketing strategies, market contribution,...

AMGN : 252.36 (+1.65%)
BMY : 66.25 (-0.73%)
MRK : 82.46 (-0.88%)
NVS : 96.92 (+0.24%)
PFE : 36.50 (-0.63%)
U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo(R) (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Opdivo(R) (nivolumab), in combination...

BMY : 66.25 (-0.73%)
U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo(R) (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer

--Application based on Phase 3 CheckMate -577 trial, in which Opdivo doubled median disease-free survival versus placebo in patients with esophageal or gastroesophageal junction cancer following neoadjuvant...

BMY : 66.25 (-0.73%)
Skin Cancer Diagnostics and Therapeutics Market Research 2020, Consumption, Companies , Industry Report Analysis and Future Demand By 2025

Japan, Japan, Wed, 20 Jan 2021 03:01:00 / Comserve Inc. / -- The report offers overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments...

AMGN : 252.36 (+1.65%)
BMY : 66.25 (-0.73%)
MRK : 82.46 (-0.88%)
NVS : 96.92 (+0.24%)
PFE : 36.50 (-0.63%)
AstraZeneca (AZN) Gets EU Nod for Improved Imfinzi Dosing

AstraZeneca's (AZN) four-week, fixed-dose regimen (1500 mg) of Imfinzi will reduce patients's medical visits by half, thereby improving patent convenience.

AZN : 52.24 (-0.63%)
PFE : 36.50 (-0.63%)
MRK : 82.46 (-0.88%)
BMY : 66.25 (-0.73%)
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know

Bristol-Myers Squibb (BMY) closed the most recent trading day at $66.54, moving +0.79% from the previous trading session.

BMY : 66.25 (-0.73%)
BeiGene (BGNE) Up on Label Expansion of Tislelizumab in China

BeiGene (BGNE) gains following the approval of tislelizumab for the lucrative indication of advanced squamous non-small cell lung cancer in China.

NVS : 96.92 (+0.24%)
BMY : 66.25 (-0.73%)
AMGN : 252.36 (+1.65%)
BGNE : 362.80 (+1.72%)
Lexicon (LXRX) Soars on FDA Permission for Sotagliflozin NDA

Lexicon (LXRX) announces that data from two late-stage studies on its type II diabetes candidate, sotagliflozin, can support a regulatory approval application.

SNY : 49.91 (-1.19%)
BMY : 66.25 (-0.73%)
HALO : 47.67 (-1.24%)
LXRX : 7.61 (-4.10%)
Harpoon's (HARP) Multiple Myeloma Candidate Gets Orphan Drug Tag

Harpoon (HARP) gets Orphan Drug designation by the FDA for HPN217 for the treatment of multiple myeloma.

JNJ : 162.38 (-0.25%)
BMY : 66.25 (-0.73%)
BLUE : 47.88 (-3.29%)
HARP : 23.76 (-1.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products. It offers products which includes hematology, oncology, cardiovascular and immunology. Bristol-Myers Squibb Company, formerly known as Bristol-Myers Company, is based in...

See More

Key Turning Points

3rd Resistance Point 67.53
2nd Resistance Point 67.18
1st Resistance Point 66.71
Last Price 66.25
1st Support Level 65.89
2nd Support Level 65.54
3rd Support Level 65.07

See More

52-Week High 68.34
Last Price 66.25
Fibonacci 61.8% 59.71
Fibonacci 50% 57.05
Fibonacci 38.2% 54.39
52-Week Low 45.76

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar